MASTER DAPT

Overview

Investigator-initiated

global randomized study

4,579 patients,

140 hospital worldwide, 30 countries

All-comers trial in

HBR patients after PCI

Abbreviated vs prolonged

DAPT in patients treated with

the Utltimaster™and Ultimaster™ Tansei™ DES

DAPT in patients
treated with the
Ultimaster™ and
Ultimaster™Tansei™
DES

Study Design

Primary Endpoint

・Net adverse clinical events (NACE) defined as a composite of death from any cause, myocardial infarction, stroke or major bleeding.

・Major adverse cardiac and cerebrovascular events (MACCE), defined as a composite of death from any cause, myocardial infarction, stroke or major bleeding.

・Major or clinically relevant non-major bleeding (MCB), defined as BARC 2, 3 or 5 bleeding.

Result

NACE

Difference in cumulative incidence,
0.23 percentage points (95% CI, 1.80 to 1.33)
P<0.001 for noninferiority

MACCE

Diﬀerence in cumulative incidence,

0.11 percentage points (95% CI, 1.29 to 1.51)

P=0.001 for noninferiority

Major or clinically relevant non-major bleeding

Diﬀerence in cumulative incidence,
-2.82 percentage points (95% CI, 4.40 to 1.24)
P<0.001 for superiority

Movie

ESC TV @ #ESCCongress 2021

Speaker - Dr. Marco

Interview about MASTR DAPT Trial

Reference

MASTER DAPT study is sponsored by the European Cardiovascular Research Institute (ECRI, Rotterdam, The Netherlands) and supported with a restricted research grant by Terumo Europe.

Related Clinical Evidences